{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:03:21Z","timestamp":1793815401563,"version":"4.6.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Key Research and Development Program of China","award":["2021YFC2501800"],"award-info":[{"award-number":["2021YFC2501800"]}]},{"name":"Leader Project of Henan Province Health Young and Middle-aged Professor","award":["HNSWJW2020013"],"award-info":[{"award-number":["HNSWJW2020013"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The effect of angiotensin-converting enzyme inhibitors (ACEIs)\/angiotensin receptor blockers (ARBs) on mortality was preliminarily explored through the comparison of ACEIs\/ARBs with non-ACEIs\/ARBs in patients with coronavirus disease 2019 (COVID-19). Reaching a conclusion on whether previous ACEI\/ARB treatment should be continued in view of the different ACE2 levels in the comparison groups was not unimpeachable. Therefore, this study aimed to further elucidate the effect of ACEI\/ARB continuation on hospital mortality, intensive care unit (ICU) admission, and invasive mechanical ventilation (IMV) in the same patient population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We searched PubMed, the Cochrane Library, Ovid, and Embase for relevant articles published between December 1, 2019 and April 30, 2022. Continuation of ACEI\/ARB use after hospitalization due to COVID-19 was considered as an exposure and discontinuation of ACEI\/ARB considered as a control. The primary outcome was hospital mortality, and the secondary outcomes included 30-day mortality, rate of ICU admission, IMV, and other clinical outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Seven observational studies and four randomized controlled trials involving 2823 patients were included. The pooled hospital mortality in the continuation group (13.04%, 158\/1212) was significantly lower than that (22.15%, 278\/1255) in the discontinuation group (risk ratio [RR]\u2009=\u20090.45; 95% confidence interval [CI], 0.28\u20130.72; P\u2009=\u20090.001). Continuation of ACEI\/ARB use was associated with lower rates of ICU admission (10.5% versus 16.2%, RR\u2009=\u20090.63; 95% CI 0.5\u20130.79; P\u2009&lt;\u20090.0001) and IMV (8.2% versus 12.5%, RR\u2009=\u20090.62; 95% CI 0.46\u20130.83, P\u2009=\u20090.001). Nevertheless, the effect was mainly demonstrated in the observational study subgroup (P\u2009&lt;\u20090.05). Continuing ACEI\/ARB had no significant effect on 30-day mortality (P\u2009=\u20090.34), acute myocardial infarction (P\u2009=\u20090.08), heart failure (P\u2009=\u20090.82), and acute kidney injury after hospitalization (P\u2009=\u20090.98).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Previous ACEI\/ARB treatment could be continued since it was associated with lower hospital deaths, ICU admission, and IMV in patients with COVID-19, although the benefits of continuing use were mainly shown in observational studies. More evidence from multicenter RCTs are still needed to increase the robustness of the data.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> PROSPERO (CRD42022341169). Registered 27 June 2022<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-023-07994-7","type":"journal-article","created":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T13:03:54Z","timestamp":1674565434000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effect of continuing the use of renin\u2013angiotensin system inhibitors on mortality in patients hospitalized for coronavirus disease 2019: a systematic review, meta-analysis, and meta-regression analysis"],"prefix":"10.1186","volume":"23","author":[{"given":"Qi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-ju","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-heng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin-bin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao-qing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-chang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,24]]},"reference":[{"key":"7994_CR1","doi-asserted-by":"publisher","first-page":"43636","DOI":"10.1007\/s11356-022-20010-w","volume":"29","author":"MF Bashir","year":"2022","unstructured":"Bashir MF, Sadiq M, Talbi B, Shahzad L, Adnan Bashir M. An outlook on the development of renewable energy, policy measures to reshape the current energy mix, and how to achieve sustainable economic growth in the post COVID-19 era. Environ Sci Pollut Res Int. 2022;29:43636\u201347.","journal-title":"Environ Sci Pollut Res Int"},{"key":"7994_CR2","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1001\/jama.2020.12839","volume":"324","author":"WJ Wiersinga","year":"2020","unstructured":"Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324:782\u201393.","journal-title":"JAMA"},{"key":"7994_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, et al. SARS-CoV-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271\u201380.","journal-title":"Cell"},{"key":"7994_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1183\/13993003.00912-2020","volume":"56","author":"NE Ingraham","year":"2020","unstructured":"Ingraham NE, Barakat AG, Reilkoff R, Bezdicek T, Schacker T, Chipman JG, Tignanelli CJ, Puskarich MA. Understanding the renin\u2013angiotensin\u2013aldosterone-SARS-CoV axis: a comprehensive review. Eur Respir J. 2020;56:1.","journal-title":"Eur Respir J"},{"key":"7994_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1124\/jpet.102.037382","volume":"303","author":"S Raiden","year":"2002","unstructured":"Raiden S, Nahmod K, Nahmod V, Semeniuk G, Pereira Y, Alvarez C, Giordano M, Geffner JR. Nonpeptide antagonists of AT1 receptor for angiotensin II delay the onset of acute respiratory distress syndrome. J Pharmacol Exp Ther. 2002;303:45\u201351.","journal-title":"J Pharmacol Exp Ther"},{"key":"7994_CR6","first-page":"71","volume":"18","author":"I Gopallawa","year":"2014","unstructured":"Gopallawa I, Uhal BD. Molecular and cellular mechanisms of the inhibitory effects of ACE-2\/ANG1-7\/Mas axis on lung injury. Curr Top Pharmacol. 2014;18:71\u201380.","journal-title":"Curr Top Pharmacol"},{"key":"7994_CR7","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s41581-020-0279-4","volume":"16","author":"AM South","year":"2020","unstructured":"South AM, Tomlinson L, Edmonston D, Hiremath S, Sparks MA. Controversies of renin\u2013angiotensin system inhibition during the COVID-19 pandemic. Nat Rev Nephrol. 2020;16:305\u20137.","journal-title":"Nat Rev Nephrol"},{"key":"7994_CR8","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1001\/jama.2020.11301","volume":"324","author":"EL Fosbol","year":"2020","unstructured":"Fosbol EL, Butt JH, Ostergaard L, Andersson C, Selmer C, Kragholm K, Schou M, Phelps M, Gislason GH, Gerds TA, et al. Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with covid-19 diagnosis and mortality. JAMA. 2020;324:168\u201377.","journal-title":"JAMA"},{"key":"7994_CR9","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","volume":"126","author":"P Zhang","year":"2020","unstructured":"Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, Liu YM, Zhao YC, Huang X, Lin L, et al. Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020;126:1671\u201381.","journal-title":"Circ Res"},{"key":"7994_CR10","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","volume":"111","author":"CM Ferrario","year":"2005","unstructured":"Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, Gallagher PE. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111:2605\u201310.","journal-title":"Circulation"},{"key":"7994_CR11","doi-asserted-by":"publisher","first-page":"F398","DOI":"10.1152\/ajprenal.90488.2008","volume":"296","author":"MJ Soler","year":"2009","unstructured":"Soler MJ, Ye M, Wysocki J, William J, Lloveras J, Batlle D. Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan. Am J Physiol Renal Physiol. 2009;296:F398-405.","journal-title":"Am J Physiol Renal Physiol"},{"key":"7994_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","volume":"23","author":"CB Jackson","year":"2022","unstructured":"Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 2022;23:3\u201320.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"7994_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/cells10071814","volume":"10","author":"T Karthika","year":"2021","unstructured":"Karthika T, Joseph J, Das VRA, Nair N, Charulekha P, Roji MD, Raj VS. SARS-CoV-2 cellular entry is independent of the ACE2 cytoplasmic domain signaling. Cells. 2021;10:7.","journal-title":"Cells"},{"key":"7994_CR14","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1186\/s13054-020-03195-9","volume":"24","author":"CL Onweni","year":"2020","unstructured":"Onweni CL, Zhang YS, Caulfield T, Hopkins CE, Fairweather L, Freeman WD. ACEI\/ARB therapy in COVID-19: the double-edged sword of ACE2 and SARS-CoV-2 viral docking. Crit Care. 2020;24:475.","journal-title":"Crit Care"},{"key":"7994_CR15","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1002\/jmv.26625","volume":"93","author":"Y Wang","year":"2021","unstructured":"Wang Y, Chen B, Li Y, Zhang L, Wang Y, Yang S, Xiao X, Qin Q. The use of renin\u2013angiotensin\u2013aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: a systematic review and meta-analysis. J Med Virol. 2021;93:1370\u20137.","journal-title":"J Med Virol"},{"key":"7994_CR16","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1097\/HJH.0000000000002784","volume":"39","author":"C Bavishi","year":"2021","unstructured":"Bavishi C, Whelton PK, Mancia G, Corrao G, Messerli FH. Renin\u2013angiotensin-system inhibitors and all-cause mortality in patients with COVID-19: a systematic review and meta-analysis of observational studies. J Hypertens. 2021;39:784\u201394.","journal-title":"J Hypertens"},{"key":"7994_CR17","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1093\/ehjcvp\/pvaa074","volume":"6","author":"A Greco","year":"2020","unstructured":"Greco A, Buccheri S, D\u2019Arrigo P, Calderone D, Agnello F, Monte M, Milluzzo RP, Franchina AG, Ingala S, Capodanno D. Outcomes of renin\u2013angiotensin\u2013aldosterone system blockers in patients with COVID-19: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2020;6:335\u20137.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"7994_CR18","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1093\/ehjcvp\/pvaa064","volume":"7","author":"A Grover","year":"2021","unstructured":"Grover A, Oberoi M. A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Eur Heart J Cardiovasc Pharmacother. 2021;7:148\u201357.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"7994_CR19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1136\/thoraxjnl-2020-215322","volume":"76","author":"HW Lee","year":"2021","unstructured":"Lee HW, Yoon CH, Jang EJ, Lee CH. Renin\u2013angiotensin system blocker and outcomes of COVID-19: a systematic review and meta-analysis. Thorax. 2021;76:479\u201386.","journal-title":"Thorax"},{"key":"7994_CR20","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1093\/eurheartj\/ehaa235","volume":"41","author":"GM Kuster","year":"2020","unstructured":"Kuster GM, Pfister O, Burkard T, Zhou Q, Twerenbold R, Haaf P, Widmer AF, Osswald S. SARS-CoV2: should inhibitors of the renin\u2013angiotensin system be withdrawn in patients with COVID-19? Eur Heart J. 2020;41:1801\u20133.","journal-title":"Eur Heart J"},{"key":"7994_CR21","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1001\/jama.2020.8946","volume":"323","author":"AB Patel","year":"2020","unstructured":"Patel AB, Verma A. COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence? JAMA. 2020;323:1769\u201370.","journal-title":"JAMA"},{"key":"7994_CR22","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","volume":"382","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin\u2013angiotensin\u2013aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;382:1653\u20139.","journal-title":"N Engl J Med"},{"key":"7994_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA, Group P-P. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.","journal-title":"Syst Rev"},{"key":"7994_CR24","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, Tugwell P. Newcastle\u2013Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2009. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed 20 May 2022."},{"key":"7994_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343: d5928.","journal-title":"BMJ"},{"key":"7994_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1471-2288-11-41","volume":"11","author":"J Bowden","year":"2011","unstructured":"Bowden J, Tierney JF, Copas AJ, Burdett S. Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics. BMC Med Res Methodol. 2011;11:41.","journal-title":"BMC Med Res Methodol"},{"key":"7994_CR27","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539\u201358.","journal-title":"Stat Med"},{"key":"7994_CR28","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"7994_CR29","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ahj.2022.04.001","volume":"249","author":"AVS Macedo","year":"2022","unstructured":"Macedo AVS, de Barros ESPGM, de Paula TC, Moll-Bernardes RJ, MendoncaDosSantos T, Mazza L, Feldman A, Arruda GDS, de Albuquerque DC, de Sousa AS, et al. Discontinuing vs. continuing ACEIs and ARBs in hospitalized patients with COVID-19 according to disease severity: insights from the BRACE CORONA trial. Am Heart J. 2022;249:86\u201397.","journal-title":"Am Heart J"},{"key":"7994_CR30","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/ehjcvp\/pvaa056","volume":"6","author":"F Cannata","year":"2020","unstructured":"Cannata F, Chiarito M, Reimers B, Azzolini E, Ferrante G, My I, Viggiani G, Panico C, Regazzoli D, Ciccarelli M, et al. Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality. Eur Heart J Cardiovasc Pharmacother. 2020;6:412\u20134.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"7994_CR31","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1093\/infdis\/jiaa447","volume":"222","author":"KW Lam","year":"2020","unstructured":"Lam KW, Chow KW, Vo J, Hou W, Li H, Richman PS, Mallipattu SK, Skopicki HA, Singer AJ, Duong TQ. Continued in-hospital angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use in hypertensive COVID-19 patients is associated with positive clinical outcome. J Infect Dis. 2020;222:1256\u201364.","journal-title":"J Infect Dis"},{"key":"7994_CR32","doi-asserted-by":"publisher","first-page":"801","DOI":"10.34067\/KID.0003792020","volume":"1","author":"I Chaudhri","year":"2020","unstructured":"Chaudhri I, Koraishy FM, Bolotova O, Yoo J, Marcos LA, Taub E, Sahib H, Bloom M, Ahmad S, Skopicki H, et al. Outcomes associated with the use of renin\u2013angiotensin\u2013aldosterone system blockade in hospitalized patients with SARS-CoV-2 infection. Kidney360. 2020;1:801\u20139.","journal-title":"Kidney360"},{"key":"7994_CR33","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1093\/ajh\/hpaa149","volume":"33","author":"A Soleimani","year":"2020","unstructured":"Soleimani A, Kazemian S, Karbalai Saleh S, Aminorroaya A, Shajari Z, Hadadi A, Talebpour M, Sadeghian H, Payandemehr P, Sotoodehnia M, et al. Effects of angiotensin receptor blockers (ARBS) on in-hospital outcomes of patients with hypertension and confirmed or clinically suspected COVID-19. Am J Hypertens. 2020;33:1102\u201311.","journal-title":"Am J Hypertens"},{"key":"7994_CR34","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/HJH.0000000000002658","volume":"39","author":"A Lahens","year":"2021","unstructured":"Lahens A, Mullaert J, Gressens S, Gault N, Flamant M, Deconinck L, Joly V, Yazdanpanah Y, Lescure FX, Vidal-Petiot E. Association between renin\u2013angiotensin\u2013aldosterone system blockers and outcome in coronavirus disease 2019: analysing in-hospital exposure generates a biased seemingly protective effect of treatment. J Hypertens. 2021;39:367\u201375.","journal-title":"J Hypertens"},{"key":"7994_CR35","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.medcli.2021.04.005","volume":"158","author":"A Aparisi","year":"2022","unstructured":"Aparisi A, Catala P, Amat-Santos IJ, Marcos-Mangas M, Lopez-Otero D, Veras C, Lopez-Pais J, Cabezon-Villalba G, Cacho Antonio CE, Candela J, et al. Chronic use of renin\u2013angiotensin\u2013aldosterone inhibitors in hypertensive COVID-19 patients: results from a Spanish registry and meta-analysis. Med Clin. 2022;158:315\u201323.","journal-title":"Med Clin"},{"key":"7994_CR36","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12916-021-01992-9","volume":"19","author":"FJ de Abajo","year":"2021","unstructured":"de Abajo FJ, Rodriguez-Miguel A, Rodriguez-Martin S, Lerma V, Garcia-Lledo A, Group M-ACS. Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study. BMC Med. 2021;19:118.","journal-title":"BMC Med"},{"key":"7994_CR37","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ahj.2022.01.015","volume":"247","author":"A Sharma","year":"2022","unstructured":"Sharma A, Elharram M, Afilalo J, Flannery A, Afilalo M, Tselios C, Ni J, Ezekowitz JA, Cheng MP, Ambrosy AP, et al. A randomized controlled trial of renin\u2013angiotensin\u2013aldosterone system inhibitor management in patients admitted in hospital with COVID-19. Am Heart J. 2022;247:76\u201389.","journal-title":"Am Heart J"},{"key":"7994_CR38","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S2213-2600(21)00214-9","volume":"9","author":"A Bauer","year":"2021","unstructured":"Bauer A, Schreinlechner M, Sappler N, Dolejsi T, Tilg H, Aulinger BA, Weiss G, Bellmann-Weiler R, Adolf C, Wolf D, et al. Discontinuation versus continuation of renin\u2013angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, andomized, controlled, open-label trial. Lancet Respir Med. 2021;9:863\u201372.","journal-title":"Lancet Respir Med"},{"key":"7994_CR39","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-2600(20)30558-0","volume":"9","author":"JB Cohen","year":"2021","unstructured":"Cohen JB, Hanff TC, William P, Sweitzer N, Rosado-Santander NR, Medina C, Rodriguez-Mori JE, Renna N, Chang TI, Corrales-Medina V, et al. Continuation versus discontinuation of renin\u2013angiotensin system inhibitors in patients admitted to hospital with COVID-19. A prospective, randomised, open-label trial. Lancet Respir Med. 2021;9:275\u201384.","journal-title":"Lancet Respir Med"},{"key":"7994_CR40","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1001\/jama.2020.25864","volume":"325","author":"RD Lopes","year":"2021","unstructured":"Lopes RD, Macedo AVS, de Barros ESPGM, Moll-Bernardes RJ, Dos Santos TM, Mazza L, Feldman A, D\u2019Andrea Saba Arruda G, de Albuquerque DC, Camiletti AS, et al. Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial. JAMA. 2021;325:254\u201364.","journal-title":"JAMA"},{"key":"7994_CR41","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nature02145","volume":"426","author":"W Li","year":"2003","unstructured":"Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450\u20134.","journal-title":"Nature"},{"key":"7994_CR42","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260\u20133.","journal-title":"Science"},{"key":"7994_CR43","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nm1267","volume":"11","author":"K Kuba","year":"2005","unstructured":"Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, Deng W, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11:875\u20139.","journal-title":"Nat Med"},{"key":"7994_CR44","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3389\/fcimb.2020.00317","volume":"10","author":"L Samavati","year":"2020","unstructured":"Samavati L, Uhal BD. ACE2, much more than just a receptor for SARS-COV-2. Front Cell Infect Microbiol. 2020;10:317.","journal-title":"Front Cell Infect Microbiol"},{"key":"7994_CR45","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1152\/physrev.00023.2016","volume":"98","author":"RAS Santos","year":"2018","unstructured":"Santos RAS, Sampaio WO, Alzamora AC, Motta-Santos D, Alenina N, Bader M, Campagnole-Santos MJ. The ACE2\/angiotensin-(1\u20137)\/MAS axis of the renin\u2013angiotensin system: focus on angiotensin-(1\u20137). Physiol Rev. 2018;98:505\u201353.","journal-title":"Physiol Rev"},{"key":"7994_CR46","doi-asserted-by":"publisher","first-page":"224","DOI":"10.2174\/1871528113666140713164506","volume":"13","author":"RR Gaddam","year":"2014","unstructured":"Gaddam RR, Chambers S, Bhatia M. ACE and ACE2 in inflammation: a tale of two enzymes. Inflamm Allergy Drug Targets. 2014;13:224\u201334.","journal-title":"Inflamm Allergy Drug Targets"},{"key":"7994_CR47","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature03712","volume":"436","author":"Y Imai","year":"2005","unstructured":"Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436:112\u20136.","journal-title":"Nature"},{"key":"7994_CR48","doi-asserted-by":"publisher","first-page":"6791","DOI":"10.1038\/s41467-021-27097-8","volume":"12","author":"T Yamaguchi","year":"2021","unstructured":"Yamaguchi T, Hoshizaki M, Minato T, Nirasawa S, Asaka MN, Niiyama M, Imai M, Uda A, Chan JF, Takahashi S, et al. ACE2-like carboxypeptidase B38-CAP protects from SARS-CoV-2-induced lung injury. Nat Commun. 2021;12:6791.","journal-title":"Nat Commun"},{"key":"7994_CR49","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/ddr.21656","volume":"81","author":"D Gurwitz","year":"2020","unstructured":"Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020;81:537\u201340.","journal-title":"Drug Dev Res"},{"key":"7994_CR50","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1001\/jamacardio.2020.1855","volume":"5","author":"N Mehta","year":"2020","unstructured":"Mehta N, Kalra A, Nowacki AS, Anjewierden S, Han Z, Bhat P, Carmona-Rubio AE, Jacob M, Procop GW, Harrington S, et al. Association of use of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers with testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5:1020\u20136.","journal-title":"JAMA Cardiol"},{"key":"7994_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.703661","volume":"8","author":"R Singh","year":"2021","unstructured":"Singh R, Rathore SS, Khan H, Bhurwal A, Sheraton M, Ghosh P, Anand S, Makadia J, Ayesha F, Mahapure KS, et al. Mortality and severity in COVID-19 patients on ACEIs and ARBs\u2014a systematic review, meta-analysis, and meta-regression analysis. Front Med. 2021;8: 703661.","journal-title":"Front Med"},{"key":"7994_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.609857","volume":"8","author":"XC Dai","year":"2021","unstructured":"Dai XC, An ZY, Wang ZY, Wang ZZ, Wang YR. Associations between the use of renin\u2013angiotensin system inhibitors and the risks of severe Covid-19 and mortality in covid-19 patients with hypertension: a meta-analysis of observational studies. Front Cardiovasc Med. 2021;8: 609857.","journal-title":"Front Cardiovasc Med"},{"key":"7994_CR53","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.3594","volume":"4","author":"R Baral","year":"2021","unstructured":"Baral R, Tsampasian V, Debski M, Moran B, Garg P, Clark A, Vassiliou VS. Association between renin\u2013angiotensin\u2013aldosterone system inhibitors and clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. JAMA Netw Open. 2021;4: e213594.","journal-title":"JAMA Netw Open"},{"key":"7994_CR54","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.dsx.2020.06.047","volume":"14","author":"R Pranata","year":"2020","unstructured":"Pranata R, Permana H, Huang I, Lim MA, Soetedjo NNM, Supriyadi R, Soeroto AY, Alkatiri AA, Firman D, Lukito AA. The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Diabetes Metab Syndr. 2020;14:983\u201390.","journal-title":"Diabetes Metab Syndr"},{"key":"7994_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30116-8","volume":"8","author":"L Fang","year":"2020","unstructured":"Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8: e21.","journal-title":"Lancet Respir Med"},{"key":"7994_CR56","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1093\/cid\/ciaa329","volume":"71","author":"TC Hanff","year":"2020","unstructured":"Hanff TC, Harhay MO, Brown TS, Cohen JB, Mohareb AM. Is there an association between Covid-19 mortality and the renin\u2013angiotensin system? A call for epidemiologic investigations. Clin Infect Dis. 2020;71:870\u20134.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"7994_CR57","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12916-020-01659-x","volume":"18","author":"P Bidulka","year":"2020","unstructured":"Bidulka P, Fu EL, Leyrat C, Kalogirou F, McAllister KS, Kingdon EJ, Mansfield KE, Iwagami M, Smeeth L, Clase CM, et al. Stopping renin\u2013angiotensin system blockers after acute kidney injury and risk of adverse outcomes: parallel population-based cohort studies in English and Swedish routine care. BMC Med. 2020;18(1):195.","journal-title":"BMC Med"},{"issue":"6","key":"7994_CR58","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1093\/ckj\/sfac003","volume":"15","author":"RJ Janse","year":"2022","unstructured":"Janse RJ, Fu EL, Clase CM, Tomlinson L, Lindholm B, van Diepen M, Dekker FW, Carrero JJ. Stopping versus continuing renin\u2013angiotensin-system inhibitors after acute kidney injury and adverse clinical outcomes: an observational study from routine care data. Clin Kidney J. 2022;15(6):1109\u201319.","journal-title":"Clin Kidney J"},{"key":"7994_CR59","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ahj.2021.09.014","volume":"243","author":"Y Xu","year":"2022","unstructured":"Xu Y, Fu EL, Trevisan M, Jernberg T, Sjolander A, Clase CM, Carrero JJ. Stopping renin\u2013angiotensin system inhibitors after hyperkalemia and risk of adverse outcomes. Am Heart J. 2022;243:177\u201386.","journal-title":"Am Heart J"},{"key":"7994_CR60","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41420-020-0276-1","volume":"6","author":"MC Gagliardi","year":"2020","unstructured":"Gagliardi MC, Tieri P, Ortona E, Ruggieri A. ACE2 expression and sex disparity in COVID-19. Cell Death Discov. 2020;6:37.","journal-title":"Cell Death Discov"},{"key":"7994_CR61","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/14737140.2021.1837628","volume":"21","author":"Y Liu","year":"2021","unstructured":"Liu Y, Lu H, Wang W, Liu Q, Zhu C. Clinical risk factors for mortality in patients with cancer and COVID-19: a systematic review and meta-analysis of recent observational studies. Expert Rev Anticancer Ther. 2021;21:107\u201319.","journal-title":"Expert Rev Anticancer Ther"},{"key":"7994_CR62","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11481-020-09974-z","volume":"16","author":"S Mukherjee","year":"2021","unstructured":"Mukherjee S, Pahan K. Is COVID-19 gender-sensitive? J Neuroimmune Pharmacol. 2021;16:38\u201347.","journal-title":"J Neuroimmune Pharmacol"},{"key":"7994_CR63","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/HJH.0b013e32834f04b6","volume":"30","author":"A Soro-Paavonen","year":"2012","unstructured":"Soro-Paavonen A, Gordin D, Forsblom C, Rosengard-Barlund M, Waden J, Thorn L, Sandholm N, Thomas MC, Groop PH, Finniane Study G. Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications. J Hypertens. 2012;30:375\u201383.","journal-title":"J Hypertens"},{"key":"7994_CR64","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/1753-0407.13085","volume":"12","author":"A Rajpal","year":"2020","unstructured":"Rajpal A, Rahimi L, Ismail-Beigi F. Factors leading to high morbidity and mortality of COVID-19 in patients with type 2 diabetes. J Diabetes. 2020;12:895\u2013908.","journal-title":"J Diabetes"},{"key":"7994_CR65","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41574-020-00435-4","volume":"17","author":"S Lim","year":"2021","unstructured":"Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol. 2021;17:11\u201330.","journal-title":"Nat Rev Endocrinol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-07994-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-07994-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-07994-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T14:04:22Z","timestamp":1674569062000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-07994-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,24]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7994"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-07994-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,24]]},"assertion":[{"value":"29 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}